胃癌的医学治疗：2017 年更新。
Medical management of gastric cancer: a 2017 update.
机构信息
Department of Internal Medicine, Section of Medical Oncology, Attikon University Hospital, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Radiation Oncology Department, University of Thessaly, School of Health Sciences, Faculty of Medicine, Larissa, Greece.
出版信息
Cancer Med. 2018 Jan;7(1):123-133. doi: 10.1002/cam4.1274. Epub 2017 Dec 13.
Abstract
Gastric cancer remains a considerable health burden throughout the world. The Cancer Genome Atlas (TCGA) analysis has recently unveiled 4 genotypes of gastric cancer with data not ready to change treatment strategy yet. A multimodality approach to therapy is the cornerstone of screening, diagnosing, staging, treating and supporting patients with gastric cancer. The evidence-based approach to localized gastric cancer (>cT1b) is to use an either preoperative or postoperative strategy to maximize the benefit of surgery. The focus of future research is to optimize chemotherapy regimens, determine the role of radiation therapy and investigate the effect of treatment timing. In metastatic gastric cancer, biologic therapies have been introduced targeting markers shown to be prognostic. The results of ongoing randomized controlled phase 3 trials using targeted and immunotherapy agents, either in combination or alone, have the potential to alter the current treatment landscape of advanced gastric cancer.
摘要
胃癌仍然是全球范围内的一个重大健康负担。癌症基因组图谱（TCGA）分析最近揭示了 4 种胃癌基因型，这些数据还不足以改变治疗策略。多模式治疗方法是筛查、诊断、分期、治疗和支持胃癌患者的基石。局部胃癌（>cT1b）的循证治疗方法是使用术前或术后策略，以最大限度地提高手术的益处。未来研究的重点是优化化疗方案，确定放疗的作用，并研究治疗时机的影响。在转移性胃癌中，已经引入了针对已证明具有预后价值的标志物的生物治疗方法。正在进行的使用靶向和免疫治疗药物的随机对照 3 期试验的结果，无论是联合使用还是单独使用，都有可能改变晚期胃癌的当前治疗格局。
相似文献
1
Medical management of gastric cancer: a 2017 update.胃癌的医学治疗：2017 年更新。
Cancer Med. 2018 Jan;7(1):123-133. doi: 10.1002/cam4.1274. Epub 2017 Dec 13.
2
Updated evidence on adjuvant treatments for gastric cancer.胃癌辅助治疗的最新证据。
Expert Rev Gastroenterol Hepatol. 2015;9(12):1549-60. doi: 10.1586/17474124.2015.1094373. Epub 2015 Sep 28.
3
Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.多中心 III 期随机对照临床试验研究方案，旨在评估新辅助化疗（NAC）联合新辅助腹腔镜腹腔内热化疗（NLHIPEC）序贯 R0 胃切除术后术中腹腔内热化疗（HIPEC）治疗进展期胃癌（AGC）的疗效：龙 II 试验。
BMC Cancer. 2020 Mar 17;20(1):224. doi: 10.1186/s12885-020-6701-2.
4
KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer.KEYNOTE-585：帕博利珠单抗联合或不联合围手术期化疗用于胃癌的 III 期研究。
Future Oncol. 2019 Mar;15(9):943-952. doi: 10.2217/fon-2018-0581. Epub 2019 Feb 19.
5
Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol.白蛋白结合型紫杉醇辅助治疗联合 S-1 对比奥沙利铂联合卡培他滨用于 D2 胃切除术后 III 期胃腺癌患者的 III 期多中心、开放标签、随机对照临床试验方案。
BMC Cancer. 2021 Jan 12;21(1):56. doi: 10.1186/s12885-020-07772-7.
6
Novel perspectives for the treatment of gastric cancer: from a global approach to a personalized strategy.治疗胃癌的新视角：从全球方法到个体化策略。
Curr Oncol Rep. 2010 May;12(3):175-85. doi: 10.1007/s11912-010-0101-8.
7
Adjuvant and neoadjuvant therapy for gastric cancer.胃癌的辅助治疗和新辅助治疗。
Semin Oncol. 1996 Jun;23(3):379-89.
8
Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.可切除胃癌化疗反应的预测性检测：多队列、回顾性分析。
Lancet Oncol. 2018 May;19(5):629-638. doi: 10.1016/S1470-2045(18)30108-6. Epub 2018 Mar 19.
9
[Current status and research progress of perioperative chemotherapy in advanced gastric cancer].[进展期胃癌围手术期化疗的现状与研究进展]
Zhonghua Wei Chang Wai Ke Za Zhi. 2015 Oct;18(10):983-5.
10
Adjuvant therapy for locally advanced gastric cancer.局部晚期胃癌的辅助治疗。
Surg Today. 2017 Nov;47(11):1295-1302. doi: 10.1007/s00595-017-1493-y. Epub 2017 Mar 1.
引用本文的文献
1
Integrative single-cell and spatial transcriptomics uncover ELK4-mediated mechanisms in + tumor cells driving gastric cancer progression, metabolic reprogramming, and immune evasion.整合单细胞和空间转录组学揭示ELK4介导的肿瘤细胞驱动胃癌进展、代谢重编程和免疫逃逸的机制。
Front Immunol. 2025 Jul 4;16:1591123. doi: 10.3389/fimmu.2025.1591123. eCollection 2025.
2
Hormonally upregulated neu tumor-associated kinase (HUNK) modulates gastric cancer progression through the regulation of cell homeostasis.激素上调的神经肿瘤相关激酶（HUNK）通过调节细胞稳态来调控胃癌进展。
Cell Commun Signal. 2025 Jul 1;23(1):320. doi: 10.1186/s12964-025-02329-2.
3
Role of Soluble Cytokine Receptors in Gastric Cancer Development and Chemoresistance.可溶性细胞因子受体在胃癌发生发展及化疗耐药中的作用
Int J Mol Sci. 2025 Mar 12;26(6):2534. doi: 10.3390/ijms26062534.
4
Development and Characterization of 4A7: A High-Affinity Monoclonal Antibody Targeting Claudin18.2.4A7的开发与表征：一种靶向Claudin18.2的高亲和力单克隆抗体
Immunotargets Ther. 2025 Mar 11;14:189-203. doi: 10.2147/ITT.S494696. eCollection 2025.
5
Treatment patterns and outcomes in advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in China.中国晚期或转移性胃/胃食管交界腺癌的治疗模式与结局
Future Oncol. 2025 Apr;21(10):1179-1188. doi: 10.1080/14796694.2025.2476930. Epub 2025 Mar 17.
6
NPC intracellular cholesterol transporter 2 regulates the anti-apoptotic protein baculoviral inhibitor of apoptosis repeat containing 3 and affects drug resistance in gastric cancer.NPC细胞内胆固醇转运蛋白2调节抗凋亡蛋白杆状病毒凋亡重复序列包含蛋白3，并影响胃癌的耐药性。
Cytojournal. 2025 Jan 23;22:7. doi: 10.25259/Cytojournal_116_2024. eCollection 2025.
7
Patients' experiences in early satiety after total gastrectomy for gastric cancer: a phenomenological study.胃癌全胃切除术后患者早期饱腹感的体验：一项现象学研究。
Front Nutr. 2025 Jan 3;11:1511113. doi: 10.3389/fnut.2024.1511113. eCollection 2024.
8
Predictive Mortality and Gastric Cancer Risk Using Clinical and Socio-Economic Data: A Nationwide Multicenter Cohort Study.利用临床和社会经济数据预测死亡率和胃癌风险：一项全国性多中心队列研究
Cancers (Basel). 2024 Dec 25;17(1):30. doi: 10.3390/cancers17010030.
9
Apatinib and gamabufotalin co-loaded lipid/Prussian blue nanoparticles for synergistic therapy to gastric cancer with metastasis.载有阿帕替尼和蟾毒灵的脂质/普鲁士蓝纳米颗粒用于协同治疗转移性胃癌。
J Pharm Anal. 2024 May;14(5):100904. doi: 10.1016/j.jpha.2023.11.011. Epub 2023 Nov 29.
10
Extracellular vesicles from : roles in the malignant phenotypes of gastric cancer.外泌体在胃癌恶性表型中的作用。
Cell Cycle. 2024 Feb;23(3):294-307. doi: 10.1080/15384101.2024.2324587. Epub 2024 Mar 6.
本文引用的文献
1
Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501).随机 III 期临床试验：胃切除术联合或不联合新辅助 S-1 加顺铂治疗 4 型或大型 3 型胃癌的短期安全性和手术结果：日本临床肿瘤学组研究（JCOG0501）。
Gastric Cancer. 2019 Sep;22(5):1044-1052. doi: 10.1007/s10120-019-00941-z. Epub 2019 Mar 2.
2
Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.纳武利尤单抗治疗既往至少两种化疗方案治疗失败或不耐受的晚期胃或胃食管结合部腺癌患者（ONO-4538-12，ATTRACTION-2）：一项随机、双盲、安慰剂对照、III 期临床试验。
Lancet. 2017 Dec 2;390(10111):2461-2471. doi: 10.1016/S0140-6736(17)31827-5. Epub 2017 Oct 6.
3
Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project.癌症基因组图谱计划所鉴定的胃癌四种分子亚型的临床意义
Clin Cancer Res. 2017 Aug 1;23(15):4441-4449. doi: 10.1158/1078-0432.CCR-16-2211.
4
TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG.TOPGEAR：一项可切除胃癌围手术期 ECF 化疗联合或不联合术前放化疗的随机 III 期临床试验：AGITG、TROG、EORTC 和 CCTG 国际多组试验的中期结果。
Ann Surg Oncol. 2017 Aug;24(8):2252-2258. doi: 10.1245/s10434-017-5830-6. Epub 2017 Mar 23.
5
Global chemotherapy development for gastric cancer.全球胃癌化疗研究进展
Gastric Cancer. 2017 Mar;20(Suppl 1):92-101. doi: 10.1007/s10120-016-0655-8. Epub 2016 Oct 7.
6
Improving Outcomes in Resectable Gastric Cancer: A Review of Current and Future Strategies.可切除胃癌的治疗效果改善：当前及未来策略综述
Oncology (Williston Park). 2016 Jul;30(7):635-45.
7
Regorafenib for the Treatment of Advanced Gastric Cancer (INTEGRATE): A Multinational Placebo-Controlled Phase II Trial.瑞戈非尼治疗晚期胃癌（INTEGRATE）：一项多国安慰剂对照II期试验。
J Clin Oncol. 2016 Aug 10;34(23):2728-35. doi: 10.1200/JCO.2015.65.1901. Epub 2016 Jun 20.
8
Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.帕博利珠单抗治疗 PD-L1 阳性晚期胃癌患者（KEYNOTE-012）：一项多中心、开放标签、Ib 期临床试验。
Lancet Oncol. 2016 Jun;17(6):717-726. doi: 10.1016/S1470-2045(16)00175-3. Epub 2016 May 3.
9
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.随机、双盲、安慰剂对照 III 期临床试验评价阿帕替尼用于化疗耐药的晚期或转移性胃或胃食管结合部腺癌患者的疗效。
J Clin Oncol. 2016 May 1;34(13):1448-54. doi: 10.1200/JCO.2015.63.5995. Epub 2016 Feb 16.
10
Immunotherapy for Gastric Cancer: A Focus on Immune Checkpoints.胃癌的免疫治疗：聚焦免疫检查点。
Target Oncol. 2016 Aug;11(4):469-77. doi: 10.1007/s11523-016-0421-1.
Zotero 插件